Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Healthcare Sector Woos Investors (China)

This article was originally published in PharmAsia News

Executive Summary

China's health care sector is quickly emerging as a hot new target for foreign investors. Venture Capital firm FAV predicts that China will have the sixth-ranked health care market in the world by 2010. FAV also projects an industry turnover worth over $28 billion by that year. The growing market is being fueled by an aging population and an overall economic growth rate averaging between 8 percent and 9 percent since 1978. Domestic researcher ChinaVenture says health care venture capital investment rose to $31 million for the third quarter. That figure is up almost 200 percent from the second quarter of 2007. The healthy inflow of cash into the sector has also encouraged seven initial public offerings by Chinese health care companies in foreign markets so far this year. Despite the growing market, analysts say the industry can still be a risky investment, particularly when it comes to pharmaceutical research. However, insiders point out that Chinese drug companies have the advantage of an efficient drug approval system and lower R&D costs. (Click here for more

You may also be interested in...

QUOTED. 24 November 2020. Kees Wesdorp.

Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.

Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue

Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.

US FDA’s Unapproved Drug Initiative Nixed, But Without Agency Buy-In Demise May Be Short-Lived

Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts